SWISS biotech company Actelion hit back at its activist shareholder Elliott Advisors yesterday, claiming the fund was trying to force a fast sale. Elliott, which holds a six per cent stake in Actelion, has since February been demanding an overhaul of the board and management to unlock value. Its calls have escalated from querying why [...]
